Ceftezole Sodium

Producers shown on SFDA

(Record date:04/09/2021）

Producers shown on EP

Not showing any

Producer:Shenyang Sanjiu Pharmaceutical Co., Ltd., a subsidiary of China Resources Sanjiu Pharmaceutical Co., Ltd., was established in May 2009, which mainly produces anti infective drug APIs and intermediates, is the only manufacturer of Western drug APIs under China Resources Sanjiu.

The company covers an area of 200 mu and now has an annual output of 200 tons of cephalosporin API sterile powder and 250 tons of intermediates. The company has won the honorary titles of Shenyang Municipal Enterprise Technology Center and advanced unit of talent work, and the workshop has passed the new GMP certification.

Staff size:200-299 persons

Registered capital:RMB 50 million

Producer:Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.founded in 1991, is a wholly-owned subsidiary of China Resources Sanjiu Pharmaceutical Co., Ltd. 

the company has an annual total output of 450 tons of third-generation cephalosporin sterile powder, two API production lines, including four modern automatic production lines for powder injection, and an annual output of 200 million powder injection preparations; The main products of China Resources Jiuxin and its subordinate enterprises include more than 30 varieties, such as cefazolin sodium pentahydrate for injection, cefuroxime sodium for injection, cefonicid sodium for injection, cefotaxime sodium for injection and ceftizole sodium for injection; At the same time, we also produce sterile APIs and intermediates, and the product quality has reached the international advanced level.

Staff size:500-599 persons

Registered capital:RMB 500 million

Producer:Zhejiang Dongying Pharmaceutical Co., Ltd. was established in 2005 and was wholly acquired by Zhejiang Guobang Pharmaceutical Co., Ltd. in March 2013. All products of the company have passed the national pharmaceutical GMP certification and are committed to the R & D, production and operation of cephalosporin antibiotics. It has an annual production capacity of 150 tons of cephalosporin sterile API, 600 tons of oral cephalosporin API and 1000 tons of pharmaceutical intermediates.

Staff size:100-199 persons

Registered capital:RMB 234 million 57 thousand and 776

Producer:CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.is a joint venture invested and established by CSPC Pharmaceutical Group Co., Ltd. in the mainland. It is a professional production base of antibiotic raw materials and preparations in China and a major supplier of non patented drugs in China. The market share of amoxicillin dispersible tablets and Amoxicillin Capsules produced by the company ranks first in the industry.

The "zero defect items" of cephalosporin powder injection, tablet and capsule passed the FDA certification for the first time; The annual output is 1.2 billion powder injections, 4.4 billion capsules and 800 million tablets; It is divided into four dosage forms: powder injection, capsule, tablet and granule; More than 150 specifications of antibiotics were produced. All kinds of products have passed GMP certification and meet the latest national standards.

Staff size:2000-2999 persons
Registered capital:RMB 678 million 555 thousand and 900

Producer:Suzhou Dawnrays Pharmaceutical Co., Ltd.is subordinate to Dawnrays pharmaceutical Co., Ltd. Suzhou Dawnrays Pharmaceutical Co., Ltd., founded on December 8, 1995, is one of the earliest enterprises in China to pass the GMP certification. It is mainly engaged in the development, manufacture and sales of cephalosporin antibiotics and systemic specialty drugs.

Staff size:600-699 persons

Registered capital:USD 131.5 million

Producer:Guangxi Kelun Pharmaceutical Co., Ltd. (formerly Guilin Dahua), now subordinate to Sichuan Kelun Pharmaceutical Co., Ltd., founded on November 22, 1996, is a manufacturer of cephalosporin antibiotic API and powder injection. The plant covers a total area of 79847.29 square meters, including a construction area of 14599.49 square meters. Guangxi Kelun became the first batch of GMP compliant units in 1999. At present, the factory is the only production base of cephalosporin antibiotics in Guangxi, which is fully equipped from API to preparation.
Staff size:400-499 persons

Registered capital:RMB 60 million

Producer:Established in 2001, Guangdong Bozhou Pharmaceutical Co., Ltd. has three preparation production lines with an annual output of 30 million powder injections, 500 million tablets and 200 million capsules, as well as API production lines such as Cefpiramide, cefterem pivoxil, Cefminox Sodium, ceftizol sodium, cefnica sodium, cefathiamidine, cefpirome thioate and cefoxitin sodium, all of which have passed the national GMP certification, It covers an area of 50000 square meters.

Staff size:50-99 persons
Registered capital:RMB 20 million

Producer:Hunan Nucien Pharmaceutical Co., Ltd.(formerly Hunan Nonferrous Kaibai biopharmaceutical Co., Ltd.) focuses on the R & D, production and marketing of chemical drugs, and is committed to the R & D and industrialization of new drugs and specific drugs for major diseases and sudden diseases.     The research and development of Nan Xin pharmaceutical products is guided by the research and development of innovative drugs. The echelons of the products and existing products have been formed. Good layout has been achieved in a variety of anti influenza drugs, anti-cancer drugs, diabetic nephropathy drugs, cardiovascular and cerebrovascular drugs, anti infective drugs and so on.
Staff size:About 50 persons

Registered capital:140 million

Producer:Luoxin Pharmaceutical Group Co., Ltd. is a large pharmaceutical enterprise group integrating drug R & D, production, trade and medical and health services.

At present, the company has four manufacturing bases, including more than 50 production lines, including powder injection, lyophilized powder injection, solid preparation (including cephalosporins), spray, aerosol, pre encapsulation, large capacity injections, small volume injections, chemical raw materials, cephalosporins, and so on. There are more than ten dosage forms and more than 300 product specifications on the market. There are 48 national new drugs. The company can produce 1 billion powder injections, 500 million freeze-dried powder injections, 400 million large bottles of injections (bags), 500 million small volume injections, 7 billion tablets, 2 billion capsules, 300 million capsules, 80 million dry suspensions, 300 tons of micro pills, 1000 tons of raw materials, 30 million aerosol cans, spray ingredients, and pre encapsulated branches.

Staff size:2000-2999 persons

Registered capital:RMB 60.96 million

Producer:Fu'an Pharmaceutical (Group) Co., Ltd., established on February 25, 2004, is the first enterprise in Changshou economic and Technological Development Zone to be successfully listed on Shenzhen GEM. The company has 9 wholly-owned and holding subsidiaries.

In 2020, it was rated as one of the top 100 in China's drug R & D comprehensive strength, one of the top 100 in China's chemical drug R & D strength, one of the top 100 in Chongqing's manufacturing industry, the Key Laboratory of industry and informatization of Chongqing Economic and Information Technology Commission, Chongqing new R & D institution and post doctoral research workstation.

Staff size:About 3000 persons

Registered capital:RMB 1 billion 190 million

Producer:Qilu Antibiotics Pharmaceutical Co., Ltd.was established in 1995, specializing in the production of cephalosporin APIs. It has three series of products: sterile APIs, oral APIs and pharmaceutical intermediates. The company has 26 listed varieties.

The company is the first in the same industry in China to pass the GMP certification in China and the EDQM certification in the European Union, and has successfully passed the official certification of Australia TGA, the FDA of the United States, Japan PMDA, South Korea MFDs, Britain EDQM, Cyprus MOH and Brazil Anvisa. It has obtained 11 CEP certificates for cephalosporins including the world's first CEP certificate. At present, there are 16 CEP certificates in China.

Staff size:2000-2999 persons

Registered capital:USD 319.27 million

Producer:Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Luoxin Pharmaceutical Group Co., Ltd.

Luoxin Pharmaceutical Group Co., Ltd. is a large pharmaceutical enterprise group integrating drug R & D, production, trade and medical and health services.

Staff size:RMB 50 million

Registered capital:700-799 persons

Producer:Guangdong Liguo Pharmaceutical Co., Ltd., established in 1995, is a pharmaceutical enterprise specializing in the R & D and production of cephalosporins. The company passed the EU GMP certification in March 2013, providing a first opportunity for products to expand into the mainstream market. At present, the annual production capacity is 600 tons of sterile API and 600 tons of oral API.

Staff size:400-499 persons
Registered capital:Hong Kong dollar 97.36 million

Producer:Harbin Hejia Pharmaceutical Co., Ltd., established in May 1995, is a wholly-owned subsidiary of Hebei Hejia Pharmaceutical Technology Group Co., Ltd. its business scope is the production of chemical raw materials (cephalosporins), preparations (cephalosporins), tablets, capsules and granules. Self operated or acting as an agent for the import and export of various commodities (except for commodities and Technologies Prohibited or restricted by the state).

Staff size:100-199 persons

Registered capital:RMB 65.5 million

Producer:Harbin Pharmaceutical Group General Pharmaceutical Factory belongs to Harbin Pharmaceutical Group Co., Ltd., which is a sino-foreign joint stock enterprise. It is a key antibiotic production base in China, a national large-scale first-level pharmaceutical enterprise, and one of the 500 large industrial enterprises in China.

Founded in 1958, the factory mainly produces penicillin and cephalosporin antibiotics, with a total of more than 30 kinds of apis and 18 kinds of dosage forms. It covers an area of 1.09 million square meters and has fixed assets of 2.156 billion yuan. It also has the production capacity of 1000 tons/year of 6-APA, 800 tons/year of 7-ACA, 4300 tons/year of antibiotic apis and intermediates and 3 billion doses of powder.

Staff size:3000-3999 persons

Registered capital:/

Producer:Shandong Lukang Pharmaceutical Co., Ltd. is the first large joint-stock enterprise in the pharmaceutical industry of Shandong Province, and the controlling shareholder is Shandong Lukang Pharmaceutical Group Co., Ltd. Lukang Pharmaceutical is a national large-scale first-class enterprise and the most complete variety of domestic pharmaceutical enterprises that have passed GMP certification, and is the first enterprise in the national western medicine system to pass ISO9001 quality system certification and ISO14001 environmental system certification“ The trademark of "Lukang brand" has been officially recognized as a well-known trademark in China by the Trademark Office of the State Administration for Industry and commerce. It is one of the five international well-known brands cultivated in Shandong Province. As of December 31, 2006, the total assets of the company reached 2.43 billion yuan.

All production workshops of the company have successfully passed GMP certification; Domestic sales are distributed in East China, North China, South China, northeast, northwest and southwest, and exported to Europe, North America and Southeast Asia. The company has actively adjusted the product layout and optimized the product structure, and has formed three series of product chains with 6-APA, 7-ACA and 7-ADCA as the parent core, realizing the successful leap from traditional antibiotic production to semi synthetic antibiotic production.

Staff size:6000 persons

Registered capital:RMB 880 million 200 thousand

Producer:Jiangsu Hanstone Pharmaceutical Co., Ltd. is a modern API pharmaceutical enterprise completed and put into operation in 2005, and has become a high-tech enterprise in Jiangsu Province.

The two plant areas of the company cover an area of about 70 mu, and the investment in the new plant area is more than 60 million yuan. It mainly produces and operates chemical synthetic APIs and sterile APIs. According to the latest relevant national laws and regulations, the workshop shall be constructed according to GMP standards. Since its establishment, it has experienced more than ten domestic and international GMP certification of API. At the end of 2013, all sterile APIs of the company passed the GMP certification of 2010 version, and at the end of 2015, all non sterile APIs of the company passed the GMP certification of 2010 version, laying a good foundation for the next development of the company. The main product ranitidine hydrochloride quality and sales volume in China. It was registered by Japan DMF in November 2006 and became a qualified foreign manufacturer of Japanese API. After receiving the strict inspection of the Japanese government, the company successfully passed the GMP inspection of PMDA of Japan's Ministry of health, labor and welfare, marking that ranitidine hydrochloride of our company has become a product successfully exported to the Japanese market, paving the way for large-scale sales in the Japanese market.

Staff size:50-99 persons

Registered capital:RMB 20.36 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978